Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use
The disclosure describes compositions comprising beta-caryophyllene (BCP) and cannabidiol (CBD). The disclosure also describes compositions which further introduce low levels of THC. The disclosure further describes methods of making and using said compositions, including for the treatment of chronic pain, neurological disorders including epilepsy, addiction and inflammatory skin conditions. The disclosure further describes the use of fluorinated-CBD derivatives for treating inflammatory skin conditions.
1. A pharmaceutical composition for reducing inflammation, comprising a therapeutically effective amount of Cannabidiol (CBD) and (E)-Beta Caryophyllene ((E)-BCP), wherein the molar ratio of CBD to (E)-BCP is from about 1:2 to about 1:33.3.
2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition consists essentially of CBD and (E)-BCP.
3. The pharmaceutical composition of claim 1 , wherein at least one of CBD and (E)-BCP is an enriched active ingredient.
4. The pharmaceutical composition of claim 3 , wherein CBD and (E)-BCP are enriched active ingredients.
5. The pharmaceutical composition of claim 1 , wherein at least one of CBD and (E)-BCP is a substantially pure active ingredient.
6. The pharmaceutical composition of claim 5 , wherein CBD and (E)-BCP are substantially pure active ingredients.
7. The pharmaceutical composition of claim 1 , wherein the molar ratio of CBD to (E)-BCP is from about 1:2 to about 1:30.
8. The pharmaceutical composition of claim 1 , wherein a single dose comprises a combined CBD and (E)-BCP content of 300-500 milligrams.
9. The pharmaceutical composition of claim 1 , wherein the composition is an oral dose.
10. The pharmaceutical composition of claim 1 , wherein the composition is a parenteral injection.
11. The pharmaceutical composition of claim 1 , wherein the composition is a transdermal patch, cream or ointment.
12. The pharmaceutical composition of claim 1 , wherein the composition is an oral mucosal absorption spray.
13. The pharmaceutical composition of claim 1 , wherein the composition is substantially THC-free.
14. The pharmaceutical composition of claim 1 , wherein a single dose comprises a combined CBD and (E)-BCP content of 300-500 milligrams.
15. The pharmaceutical composition of claim 1 , wherein the composition is an oral dose.
16. The pharmaceutical composition of claim 1 , wherein the composition is a parenteral injection.
17. The pharmaceutical composition of claim 1 , wherein the composition is a transdermal patch, cream or ointment.
18. The pharmaceutical composition of claim 1 , wherein the composition is an oral mucosal absorption spray.
19. The composition of claim 1 , wherein the composition is substantially THC-free.
20. A pharmaceutical composition for treatment of inflammatory conditions, comprising a therapeutically effective a mount of Cannabidiol (CBD) and (E)-Beta Caryophyllene ((E)-BCP), wherein the molar ratio of CBD to (E)-BCP is from about 1:2 to about 1:33.3.
21. A pharmaceutical composition comprising a therapeutically effective amount of Cannabidiol (CBD) and (E)-Beta Caryophyllene ((E)-BCP), wherein the molar ratio of CBD to (E)-BCP is from about 1:2 to about 1:33.3; wherein the composition has anti-inflammatory activity.